Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T13:35:26.448Z.
Calculation as of: 2026-10-06T13:35:26.448Z.
Quote observation: 2026-10-06T13:31:50.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 237c69f2886ce95022375c2c4ca3b4be9bdf1b13d47079a179ac8fcd7ebd926e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Allarity Therapeutics, Inc.
Market Cap
$15.91M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$15.57M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$15.35M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$15.33M
Price/OCF Ratio
N/A
TTM Avg
57.00
3Y Avg
57.00
5Y Avg
57.00
Market Cap
$17.13M
Price/OCF Ratio
N/A
TTM Avg
43.53
3Y Avg
44.24
5Y Avg
48.21
Market Cap
$14.03M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | $15.91M | N/A | N/A | N/A | N/A |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.57M | N/A | N/A | N/A | N/A |
| BioCardia, Inc. (BCDA)vs › | $16.37M | N/A | 64.40 | 51.01 | 44.81 |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.35M | N/A | N/A | N/A | N/A |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.33M | N/A | 57.00 | 57.00 | 57.00 |
| Bionano Genomics, Inc. (BNGO)vs › | $16.57M | N/A | N/A | N/A | N/A |
| Lipocine Inc. (LPCN)vs › | $17.07M | N/A | N/A | N/A | N/A |
| Dyadic International, Inc. (DYAI)vs › | $17.13M | N/A | 43.53 | 44.24 | 48.21 |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.03M | N/A | N/A | N/A | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $13.76M | 26.23 | 28.16 | 28.16 | 28.16 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
